Literature DB >> 1382741

Cell membranes as barriers for antisense constructions.

V G Budker1, D G Knorre, V V Vlassov.   

Abstract

The results of studies on interaction of oligonucleotides and polynucleotides with cell membranes are reviewed. Oligonucleotides and polynucleotides bind to lipid membranes in the presence of divalent cations that may result in spontaneous encapsulation of nucleic acids and transfer of the formed vesicles to the other side of the membrane. Oligonucleotides can enter eukaryotic cells and interact with cellular RNA and DNA. On the surface of eukaryotic cells, there are proteins capable of binding to nucleic acids that may be involved in oligonucleotide uptake. Oligonucleotides bind to cellular CD4 receptors. Efficient delivery into cells can be achieved by conjugation of oligonucleotides to lipophilic groups or by encapsulation into membrane carriers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382741     DOI: 10.1089/ard.1992.2.177

Source DB:  PubMed          Journal:  Antisense Res Dev        ISSN: 1050-5261


  5 in total

Review 1.  Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.

Authors:  W Brysch; K H Schlingensiepen
Journal:  Cell Mol Neurobiol       Date:  1994-10       Impact factor: 5.046

2.  Synthesis and hybridization properties of oligonucleotides containing 2'-O-modified ribonucleotides.

Authors:  T H Keller; R Häner
Journal:  Nucleic Acids Res       Date:  1993-09-25       Impact factor: 16.971

3.  Conformation of oligodeoxynucleotides associated with anionic liposomes.

Authors:  S D Patil; D G Rhodes
Journal:  Nucleic Acids Res       Date:  2000-11-01       Impact factor: 16.971

4.  Phosphorothioate oligonucleotides inhibit the replication of lentiviruses and type D retroviruses, but not that of type C retroviruses.

Authors:  D Archambault; C A Stein; J S Cohen
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

5.  Transferrin-conjugated SNALPs encapsulating 2'-O-methylated miR-34a for the treatment of multiple myeloma.

Authors:  Immacolata Scognamiglio; Maria Teresa Di Martino; Virginia Campani; Antonella Virgilio; Aldo Galeone; Annamaria Gullà; Maria Eugenia Gallo Cantafio; Gabriella Misso; Pierosandro Tagliaferri; Pierfrancesco Tassone; Michele Caraglia; Giuseppe De Rosa
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.